Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________ FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ | --- ...

Revenue Performance - Total revenue for Q3 2024 was $89 million, a 61% increase from $55 million in the same period last year, primarily due to a $45 million non-cash revenue release[3]. - Excluding the non-cash revenue, total revenue was $44 million, representing a 21% decrease year-over-year[3]. - Total revenue for Q3 2024 was $89.046 million, a 60.6% increase from $55.430 million in Q3 2023[15]. - Cell Engineering revenue reached $75.089 million in Q3 2024, compared to $37.176 million in Q3 2023, marking a 101.5% increase[15]. - Biosecurity revenue decreased to $13.957 million in Q3 2024, down 23.5% from $18.254 million in Q3 2023[21]. Operational Loss and Expenses - Loss from operations for Q3 2024 was $(55) million, significantly improved from $(286) million in the prior year[3]. - Total operating loss for Q3 2024 was $55.204 million, significantly improved from a loss of $286.393 million in Q3 2023[21]. - Total operating expenses for Q3 2024 were $144.250 million, significantly lower than $341.823 million in Q3 2023, a decrease of 57.7%[15]. - Research and development expenses for Q3 2024 were $77.006 million, down from $156.662 million in Q3 2023, representing a 50.9% reduction[15]. - General and administrative expenses for Q3 2024 totaled $39.359 million, a decrease of 28.2% compared to $54.824 million in Q3 2023[21]. - Stock-based compensation for Q3 2024 was $14.013 million, down from $53.647 million in Q3 2023[21]. Cash and Equity - Cash and cash equivalents at the end of Q3 2024 totaled $616 million[3]. - Cash and cash equivalents at the end of the period were $616.214 million, down from $944.073 million at the beginning of the period[20]. - Total stockholders' equity decreased to $797.943 million from $1,097.152 million year-over-year[15]. Future Guidance and Goals - Ginkgo updated its 2024 revenue guidance to $215-235 million, reflecting the impact of the $45 million non-cash deferred revenue release[6]. - Ginkgo aims to achieve Adjusted EBITDA breakeven by the end of 2026, with an estimated $85 million in annualized savings from workforce reductions by mid-2025[5]. New Programs and Contracts - The company added 25 new programs and contracts in Cell Engineering during Q3 2024, including a new deal with Novo Nordisk[4]. Comprehensive Loss - The company reported a comprehensive loss of $54.417 million for Q3 2024, compared to a comprehensive loss of $304.490 million in Q3 2023[16].

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductionsGinkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck  BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The upda ...

Core Insights - Ginkgo Bioworks has completed the first milestone of its partnership with Merck, receiving a cash payment of $9 million [1][2][3] - The next phase of the partnership will focus on further improving the biologic manufacturing process [2][3] Company Overview - Ginkgo Bioworks is a leading platform for cell programming, offering end-to-end services across various markets, including pharmaceuticals and biosecurity [4] - The company emphasizes its capabilities in strain engineering, high-throughput screening, and process development, positioning itself as a valuable partner for pharmaceutical companies [3][4]

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET.The presentation details and webcast link will be ava ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $7.63, demonstrating a -1.55% swing from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.33%.The company's stock has dropped by 6.96% in the past month, falling short of the Medical sector's loss of 3.47% and the S&P 500's gain of 0.41%.Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in i ...

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also in ...

Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providin ...

NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founde ...

Market Overview - The global pet DNA testing market is projected to reach USD 676.64 million by 2030, growing at a CAGR of 9.45% from 2024 to 2030 [1][12] - The U.S. pet industry expenditure increased from USD 103.6 billion in 2020 to USD 123.6 billion in 2021, marking a 19% growth [2] Growth Drivers - Key factors driving market growth include rising consumer genomics, high pet expenditure, increased awareness of pet DNA testing products, and more R&D initiatives [2][7] - The COVID-19 pandemic led to a surge in pet adoption and spending, with owners investing more time and money in their pets [3][4] Market Segmentation - The dogs segment accounted for the largest revenue share in 2023 due to high dog adoption rates in the U.S. [9] - Saliva sample tests are the most popular, holding the largest share in 2023 [9] - Genetic diseases testing is a significant segment, with genetic DNA profiling becoming a standard in breeding programs [9] Regional Insights - North America held the largest revenue share in 2023, while the Asia Pacific region is expected to grow at the fastest CAGR from 2024 to 2030 [9] Competitive Landscape - Major players in the pet DNA testing market include Zoetis Inc., Mars Petcare, Orivet Genetic Pet Care Limited, and Embark Veterinary, Inc. [9]